Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 165

1.

Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.

Barnett PG, Scott JY, Krystal JH, Rosenheck RA; CSP 555 Research Group.

J Clin Psychiatry. 2012 May;73(5):696-702. doi: 10.4088/JCP.11m07070.

PMID:
22697193
[PubMed - indexed for MEDLINE]
2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
[PubMed - indexed for MEDLINE]
3.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
[PubMed - indexed for MEDLINE]
4.

Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.

Edwards NC, Rupnow MF, Pashos CL, Botteman MF, Diamond RJ.

Pharmacoeconomics. 2005;23(3):299-314.

PMID:
15836010
[PubMed - indexed for MEDLINE]
5.

Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.

Rosenheck RA, Krystal JH, Lew R, Barnett PG, Thwin SS, Fiore L, Valley D, Huang GD, Neal C, Vertrees JE, Liang MH; CSP 555 Research Group.

Clin Trials. 2011 Apr;8(2):196-204. doi: 10.1177/1740774510392931. Epub 2011 Jan 26.

PMID:
21270143
[PubMed - indexed for MEDLINE]
6.

Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Edwards NC, Locklear JC, Rupnow MF, Diamond RJ.

Pharmacoeconomics. 2005;23 Suppl 1:75-89.

PMID:
16416763
[PubMed - indexed for MEDLINE]
7.

Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.

Taylor DM, Wright T, Libretto SE; Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS) U.K. Investigator Group.

J Clin Psychiatry. 2003 May;64(5):589-97.

PMID:
12755664
[PubMed - indexed for MEDLINE]
8.

Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.

Ren XS, Crivera C, Sikirica M, Dirani R, Qian S, Kazis LE.

J Clin Pharm Ther. 2011 Jun;36(3):383-9. doi: 10.1111/j.1365-2710.2010.01211.x. Epub 2010 Nov 10.

PMID:
21062329
[PubMed - indexed for MEDLINE]
9.

Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.

Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R.

Value Health. 2006 Mar-Apr;9(2):77-89.

PMID:
16626411
[PubMed - indexed for MEDLINE]
10.

Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.

Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa-McMillan A.

J Clin Psychiatry. 2012 Sep;73(9):1224-33. doi: 10.4088/JCP.11m06905. Epub 2012 Aug 7.

PMID:
22938760
[PubMed - indexed for MEDLINE]
11.

Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.

Rosa F, Schreiner A, Thomas P, Sherif T.

Clin Drug Investig. 2012 Apr 1;32(4):267-79. doi: 10.2165/11599080-000000000-00000.

PMID:
22339430
[PubMed - indexed for MEDLINE]
12.

Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.

Carswell C, Wheeler A, Vanderpyl J, Robinson E.

Clin Drug Investig. 2010;30(11):777-87. doi: 10.2165/11537680-000000000-00000.

PMID:
20712387
[PubMed - indexed for MEDLINE]
13.

A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.

Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM.

J Clin Psychiatry. 2009 Oct;70(10):1397-406. doi: 10.4088/JCP.09m05284yel.

PMID:
19906343
[PubMed - indexed for MEDLINE]
14.

Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.

Yang YK, Tarn YH, Wang TY, Liu CY, Laio YC, Chou YH, Lee SM, Chen CC.

Psychiatry Clin Neurosci. 2005 Aug;59(4):385-94. Erratum in: Psychiatry Clin Neurosci. 2005 Oct;59(5):625-6. Tarn, Yeng Hui [corrected to Tarn, Yen-Huei].

PMID:
16048443
[PubMed - indexed for MEDLINE]
15.

Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia.

Leatherman SM, Liang MH, Krystal JH, Lew RA, Valley D, Thwin SS, Rosenheck RA; CSP 555 Investigators.

J Nerv Ment Dis. 2014 Jan;202(1):13-7. doi: 10.1097/NMD.0000000000000069.

PMID:
24375206
[PubMed - indexed for MEDLINE]
16.

Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise.

Heeg BM, Antunes J, Figueira ML, Jara JM, Marques Teixeira J, Palha AP, Vaz Serra A, Buskens E, Caleo S, Gouveia-Pinto C, Van Hout BA.

Curr Med Res Opin. 2008 Feb;24(2):349-58.

PMID:
18081988
[PubMed - indexed for MEDLINE]
17.

The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.

Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL.

Value Health. 2004 Jan-Feb;7(1):22-35.

PMID:
14720128
[PubMed - indexed for MEDLINE]
18.

[Pharmacoeconomic review of the use of injectable long-acting risperidone].

Bartkó G, Fehér L.

Neuropsychopharmacol Hung. 2005 Dec;7(4):199-207. Review. Hungarian.

PMID:
16496485
[PubMed - indexed for MEDLINE]
19.

How do clinical trial participants compare to other patients with schizophrenia?

Barnett PG, Scott JY, Rosenheck RA; CSP 555 Study Group.

Schizophr Res. 2011 Aug;130(1-3):34-9. doi: 10.1016/j.schres.2011.03.033. Epub 2011 Apr 22.

PMID:
21514794
[PubMed - indexed for MEDLINE]
20.

The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden.

Willis M, Svensson M, Löthgren M, Eriksson B, Berntsson A, Persson U.

Eur J Health Econ. 2010 Dec;11(6):585-94. doi: 10.1007/s10198-009-0215-9. Epub 2010 Jan 19.

PMID:
20084535
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk